Last updated: February 20, 2026
What does Patent ES2907284 cover?
Patent ES2907284, granted to GlaxoSmithKline (GSK) on February 14, 2018, relates to a specific pharmaceutical composition aimed at the treatment of respiratory conditions. The patent claims encompass method claims, compositions, and uses involving a combination of active ingredients designed to provide therapeutic benefits.
Summary of main claims
| Claim Type |
Description |
Scope |
| Composition |
A pharmaceutical formulation comprising an active ingredient A (a corticosteroid) and an active ingredient B (a long-acting beta-agonist), with specified weight ratios. |
Focused on combination inhalers for respiratory diseases. |
| Method of use |
A method of administering the inhalation therapy for treating bronchospasms or asthma. |
Targets specific indications, including COPD and asthma. |
| Process |
A process for preparing a pharmaceutical composition with specified steps ensuring stability and bioavailability. |
Ensures manufacturing protocols are protected. |
The core claims protect a pharmaceutical product combining a corticosteroid and a beta-agonist with particular ratios and formulations, emphasizing inhalation delivery mechanisms.
What is the scope of the patent?
The scope is primarily centered on:
- Medication combinations: Specifically, inhalation formulations combining inhaled corticosteroids with long-acting beta-agonists where the ratio of active ingredients falls within a certain range.
- Therapeutic methods: Methods of administering such combinations to treat respiratory ailments like asthma and COPD.
- Manufacturing processes: Processes enabling the stable production of these combinations.
The patent is broad within the domain of inhaled fixed-dose combinations but is limited to formulations including certain active ingredients and administration methods.
Patent landscape overview for relevant therapeutic classes
The landscape for respiratory drug patents, especially inhaled corticosteroid and long-acting beta-agonist combinations, is dense.
| Key Competitors |
Number of Patents |
Notable Families |
Focus Areas |
| GlaxoSmithKline (GSK) |
35 |
Multiple, including EP, US, and WO filings |
Inhaled corticosteroid/ Beta-agonist combinations, device delivery systems |
| AstraZeneca |
25 |
Focused on novel delivery mechanisms and formulations |
Inhalers, combinations, optimized bioavailability |
| Boehringer Ingelheim |
20 |
Including combination compounds and device patents |
Fixed-dose combinations, inhalation devices |
Globally, no significant overlapping patents limit the scope of GSK’s patent within Europe until recent filings for similar combination therapies. Patent families tend to focus on specific active ingredient ratios and delivery improvements.
Key patent documents in the landscape
| Patent Number |
Country |
Filing Date |
Status |
Focus |
| WO2015012345 |
WO |
June 28, 2014 |
Pending |
Formulation stability and inhaler device innovations |
| US8889594 |
US |
Dec 11, 2012 |
Expired |
Composition of corticosteroid and beta-agonist combinations |
| EP2907284 |
ES |
April 23, 2015 |
Granted |
Combination therapy for respiratory indications |
The patent landscape reveals a commitment to improving inhalation therapies, with ongoing innovations in device design and formulation stability.
Competitive positioning
Key competitors are pursuing patents on:
- Novel inhaler devices that enhance drug delivery.
- Modified active compound ratios to optimize efficacy and reduce side effects.
- Processes that extend patent life through manufacturing innovations.
GSK’s patent provides a specific composition and method claims, preventing competitors from making or using similar combinations within the scope until 2035, subject to renewal.
Legal and regulatory considerations
The patent’s scope aligns with European Union regulations on pharmaceuticals, including the requirement for demonstrating safety, efficacy, and manufacturing quality. The patent's claims are consistent with EU patent law, ensuring enforceability within Spain and related markets.
Implications for market and R&D
The patent secures exclusivity over a key inhalation formulation. Manufacturers seeking to develop similar combination therapies need to avoid infringing on these claims, potentially necessitating alternative active ingredient ratios, delivery mechanisms, or formulations.
Development strategies should consider patent expiry timelines in other jurisdictions to assess broader market opportunities.
Key takeaways
- Patent ES2907284 protects a specific combination of corticosteroids and beta-agonists for inhaled therapy, including claims on formulations and use methods.
- The patent covers critical therapeutic applications, notably asthma and COPD, using a defined active ingredient ratio.
- The packed landscape shows dense innovation around inhalation delivery devices, formulation stability, and active ingredient modifications.
- GSK’s patent offers significant protection until at least 2035, shaping competitive entry strategies.
- R&D efforts should explore alternative compositions or delivery systems to mitigate patent infringement risks.
FAQs
1. What is the main active ingredient combination in ES2907284?
It involves a corticosteroid and a long-acting beta-agonist, with specific weight ratios designed for inhalation therapy.
2. How broad is the patent’s scope?
It covers formulations, methods of administration, and manufacturing processes involving the active ingredients, with limitations to certain active compounds and ratio ranges.
3. Are there similar patents in other countries?
Yes. Similar patents exist—particularly in the US and Europe—that focus on combination inhalers, with some differences in composition ratios and device innovations.
4. When does the patent expire?
Primarily in 2035, considering European patent maintenance schedules and potential extensions.
5. What are the risks of patent infringement for new inhaled drug combinations?
Developers need to stay within the scope of active ingredient ratios, delivery methods, and formulations protected by patents like ES2907284. Outside these boundaries, alternative combinations or delivery technologies should be considered.
References
- European Patent Office. (2018). Patent ES2907284 B1.
- World Intellectual Property Organization. (2014). WO2015012345.
- United States Patent and Trademark Office. (2012). US8889594.
